Responsive drug release functional hydrogel and preparation method thereof

By introducing reactive oxygen responsive prodrugs into polyvinyl alcohol, the ROS environment on the eye surface triggers drug release, solving the problem of poor eye drop retention ability, realizing adaptive release and efficient utilization of drugs, and improving treatment effectiveness and safety.

CN118975976AActive Publication Date: 2024-11-19SHENYANG PHARMA UNIV

Patent Information

Application Number
CN202411056963.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

The existing eye drop retention ability of the treatment of bacterial keratitis is poor, resulting in low drug bioavailability, frequent administration, and large fluctuations in drug concentration, which may cause toxic side effects or drug resistance.

Method used

Develop a responsive release functional hydrogel, using polyvinyl alcohol and reactive oxygen-containing reactive oxygen-containing prodrugs to form polymer hydrogels through a freeze-thaw cycle, using the ROS environment on the eye surface to trigger drug release, realizing drug release Adaptive release.

Benefits of technology

It significantly improves the retention time and bioavailability of drugs in the eyes, reduces drug leakage, realizes the controllability and safety of drug release, reduces the occurrence of side effects, and improves the effectiveness of treatment and patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976720950000021
    Figure BDA0004976720950000021
  • Figure FDA0004976720940000011
    Figure FDA0004976720940000011
  • Figure HDA0004976720970000011
    Figure HDA0004976720970000011
Patent Text Reader

Abstract

The invention discloses a responsive drug release functional hydrogel and a preparation method thereof, and belongs to the technical field of biological medicines. The responsive drug release functional hydrogel matrix is high-molecular functional hydrogel formed by polyvinyl alcohol and polyvinyl alcohol containing one or more responsive prodrugs through freezing-unfreezing circulation to initiate physical crosslinking of a polyvinyl alcohol chain. The preparation method comprises the following steps: synthesizing a drug with carboxyl into a responsive prodrug through a two-step reaction, then connecting the responsive prodrug to a polyvinyl alcohol main chain, and finally preparing the responsive drug release functional hydrogel through a freezing-unfreezing circulation method. The functional hydrogel with responsive drug release prepared by the invention can be triggered by active oxygen at a disease part to release the drug, prolongs the action time of the drug, improves the bioavailability of the drug, and is used for personalized treatment of diseases such as inflammation or infection and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to a functional hydrogel with responsive drug release and a preparation method thereof. Background Art

[0002] Bacterial keratitis is one of the leading causes of corneal opacity and blindness. Timely and appropriate treatment is essential to prevent complications such as corneal scarring, perforation, and even permanent visual impairment. The importance of treating corneal damage is equally self-evident, as it directly affects the patient's vision and eye health. Common treatments for bacterial keratitis and corneal damage are combined use of antibiotic and anti-inflammatory eye drops to control or prevent infection and relieve inflammation and pain. Due to the poor retention capacity of eye drops, the bioavailability is extremely low, and frequent eye drops are required. This not only leads to poor patient compliance, but also causes large fluctuations in drug concentrations. When the drug concentration is high, it may cause unnecessary toxic side effects; when the drug concentration is low, it may not be enough to eradicate all bacteria and produce drug resistance.

[0003] Functional hydrogels have the functions of moisturizing and preventing secondary damage caused by blinking, which can minimize the exposure of corneal stroma; at the same time, they can also be used as drug delivery reservoirs to appropriately prolong the residence time of drugs on the ocular surface and maintain the therapeutic concentration of drugs. However, this drug delivery method still has some challenges. The use of immersion method for drug delivery often produces a higher burst release, short release time, and large fluctuations in drug concentration. In addition, preventing large amounts of hydrogel from leaking during the storage stage, resulting in inaccurate dosage, is also a major problem.

[0004] Reactive oxygen species (ROS) play a key role in inflammation and are exacerbated at sites of infection and tissue damage. These ROS play an important role in regulating inflammatory responses and defending the host against invasive microorganisms, however, uncontrolled excess ROS can further damage host cells during the wound healing response. Inspired by this, ROS-responsive drug-release hydrogels take advantage of the elevated ROS environment of corneal injury and ocular surface inflammation to achieve adaptive drug release. The drug release "switch" is turned on at the injured or infected ocular surface. Compared with other reactive oxygen species-responsive units, aryl boronates selectively respond to H2O2, exhibit excellent in vitro degradation kinetics under physiological conditions, and can stoichiometrically eliminate hydrogen peroxide, acting as a mimetic of catalase. More importantly, materials functionalized with aryl boronates show good safety characteristics in in vitro tests and in vivo evaluations in different animal models. Therefore, the development of such ROS-responsive drug delivery systems has great potential for clinical application. In this study, phenylboronic acid, an active oxygen responsive group, was used as a connecting bond. One end was combined with the drug, and the other end formed a borate ester bond with the hydrogel polymer chain. H2O2 coordinated with the boron atom and oxidized the BC bond to form a borate, which can be rapidly hydrolyzed into boric acid / ester and aromatic phenol in water, while releasing active drug molecules, achieving the purpose of on-demand drug release, that is, adjusting the drug release rate according to the severity of the disease, thereby releasing higher doses in more serious cases. Summary of the invention

[0005] In view of the above problems in the prior art, the purpose of the present invention is to provide a functional hydrogel with responsive drug release, which can release drugs under the triggering of ROS on the inflammatory ocular surface, achieve the synchronous and controllable release of drugs with different hydrophilicity and hydrophobicity, prolong the retention time, and significantly improve the bioavailability.

[0006] The present invention also aims to provide a method for preparing polyvinyl alcohol containing responsive prodrug.

[0007] The present invention also aims to provide the application of the polyvinyl alcohol containing the responsive prodrug.

[0008] In order to achieve the above purpose, the present invention adopts the following technical solutions:

[0009] The present invention provides a functional hydrogel with responsive drug release;

[0010] Furthermore, the responsive drug-releasing functional hydrogel matrix is ​​a high molecular weight functional hydrogel formed by physical cross-linking of polyvinyl alcohol chains induced by freeze-thaw cycles of polyvinyl alcohol and polyvinyl alcohol containing one or more responsive prodrugs.

[0011] Furthermore, by weight percentage, the weight percentage of each component in the hydrogel is: polyvinyl alcohol accounts for 0% to 90% of the dry weight of the matrix, polyvinyl alcohol containing one or more responsive prodrugs accounts for 10% to 100% of the dry weight of the matrix, and the total is 100%.

[0012] Furthermore, in the polyvinyl alcohol containing one or more responsive prodrugs, the weight percentage of the drug component in the matrix is ​​0.01% to 30% by weight; preferably, the weight percentage of the drug component in the matrix is ​​1% to 5% by weight.

[0013] The method for preparing the functional hydrogel with responsive drug release comprises the following steps:

[0014] Polyvinyl alcohol and polyvinyl alcohol containing one or more responsive prodrugs are placed in a mixed solvent of dimethyl sulfoxide (DMSO) and water. After heating and stirring to dissolve, it is injected into a mold, frozen at -20°C, then thawed at room temperature, and the freeze-thaw cycle is repeated. DMSO is washed away with deionized water to obtain a drug-loaded functional hydrogel with responsive drug release. Preferably, it is frozen at -20°C for 7 hours, taken out and thawed at room temperature for 3 hours, and the freeze-thaw cycle is repeated 4 times.

[0015] The polyvinyl alcohol containing one or more responsive prodrugs has the following general chemical structure formula:

[0016]

[0017] Wherein, R1 is one or more combinations of carboxyl drugs, connected to the benzene ring through an ester group. R2 indicates that the hydrogen atoms on the benzene ring can be replaced by any group. The degree of polymerization of polyvinyl alcohol is 1000 to 10000, preferably the degree of polymerization of polyvinyl alcohol is 1500 to 2000. m≥1.

[0018] The present invention provides a method for preparing the above-mentioned polyvinyl alcohol containing one or more responsive prodrugs, comprising the following steps:

[0019] (1) subjecting a carboxyl drug, hydroxymethylphenylboronic acid pinacol ester or its derivative to an esterification reaction in an organic solvent in the presence of a catalyst to obtain an intermediate compound, which is recorded as Drug-PBE;

[0020] (2) reacting the intermediate compound Drug-PBE with sodium periodate to remove pinacol to obtain an intermediate compound, which is recorded as Drug-PBA;

[0021] (3) The intermediate compound Drug-PBA undergoes an esterification reaction with the diol structure of polyvinyl alcohol to generate polyvinyl alcohol containing one or more responsive prodrugs.

[0022] Furthermore, the preparation method of the intermediate compound Drug-PBE described in step (1) is as follows: dissolving a carboxyl drug, hydroxymethylphenylboronic acid pinacol ester or its derivative, and 4-dimethylaminopyridine in an organic solvent, and stirring at room temperature for 10-15 minutes; adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stirring at room temperature for more than 12 hours under light-proof conditions, and after the reaction is completed, separating and treating by column chromatography to obtain the product Drug-PBE;

[0023] The molar ratio of the carboxyl drug, hydroxymethylphenylboronic acid pinacol ester or its derivative, 4-dimethylaminopyridine and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is (1-1.2):(1-1.2):(1-1.2):(1.2-1.5); the organic solvent is one of dichloromethane, acetonitrile and acetone; the hydroxymethylphenylboronic acid pinacol ester or its derivative is preferably 4-hydroxymethylphenylboronic acid pinacol ester.

[0024] Furthermore, the preparation method of the intermediate compound Drug-PBA described in step (2) is: dissolving the intermediate compound Drug-PBE, sodium periodate and ammonium acetate in a solvent, stirring at room temperature for more than 12 hours, and after the reaction is completed, using column chromatography to separate and treat to obtain the product Drug-PBA;

[0025] The molar ratio of the Drug-PBE, sodium periodate and ammonium acetate is (1-3):(1-3):(1-3); and the solvent is a mixed solvent of acetone and water.

[0026] Furthermore, the preparation method of the polyvinyl alcohol containing one or more responsive prodrugs described in step (3) is as follows: polyvinyl alcohol and dimethyl sulfoxide are added to a flask and heated to 90°C under stirring until completely dissolved. After dissolution, the mixture is cooled to room temperature, and the intermediate compound Drug-PBA and an organic base are added. The mixture is stirred at room temperature overnight, and the product is dialyzed in deionized water for 24-48 hours, and dried to obtain polyvinyl alcohol containing one or more responsive prodrugs;

[0027] The molar ratio of the Drug-PBA, polyvinyl alcohol and the organic base is 1:(1-20):(1-10); the organic base is one of triethylamine, trimethylamine, diisopropylethylamine, DBU and pyridine.

[0028] Furthermore, the carboxyl drug is one or more of drugs with carboxyl or modified to have carboxyl, preferably non-steroidal anti-inflammatory drugs and antibacterial drugs, more preferably diclofenac and levofloxacin.

[0029] Furthermore, the polyvinyl alcohol containing one or more responsive prodrugs is a polyvinyl alcohol molecule that only loads one drug, and polyvinyl alcohol containing multiple drugs is obtained after mixing, or a polyvinyl alcohol molecule is co-loaded with multiple drugs.

[0030] The present invention provides application of the responsive drug-releasing functional hydrogel in preparing a drug-device for treating bacterial keratitis.

[0031] The responsive drug-releasing functional hydrogel and the preparation method thereof of the present invention have the following advantages:

[0032] (1) The functional hydrogel loaded with active oxygen-responsive prodrugs designed and synthesized by the present invention has adjustable drug dosage and controllable drug release, which effectively increases the retention time of the drug in the eye and the bioavailability of the drug.

[0033] (2) Drug-loaded functional hydrogels are prepared from polyvinyl alcohol by physical cross-linking, i.e., freeze-thaw cycle method. The preparation process is simple, does not contain organic cross-linking agents, has high transmittance and good mechanical properties.

[0034] (3) There is almost no drug leakage during storage, and the disease-responsive "switch" can fully play its role, achieving effective prevention and treatment of ocular surface bacterial infection and inflammation.

[0035] (4) It is widely applicable to the development of inflammation-responsive prodrugs of various drugs containing carboxyl groups or drugs modified to carry carboxyl groups and other similar compounds, and provides ideas for responsive drug release at other inflammatory sites.

[0036] (5) The responsive drug-releasing functional hydrogel prepared by the present invention can be triggered to release drugs by reactive oxygen species in the ocular surface disease site, thereby prolonging the drug action time and improving the ocular bioavailability of the drug, and can be used for personalized treatment of diseases such as ocular surface inflammation or infection.

[0037] (6) In the present invention, the drug is connected in the polymer hydrogel by chemical bonds rather than simple infiltration. Through chemical bond connection, the rate and timeliness of drug release can be controlled more accurately; chemical bond connection usually means that the drug is more tightly and stably bound to the hydrogel. This stability can protect the drug from the influence of external conditions (such as light, moisture or temperature changes), extend the drug's shelf life, and enhance drug stability; chemical bond connection can promote the efficiency of drug delivery in the body, because the drug is fixed in the target area by the polymer hydrogel, avoiding the rapid release or loss of the drug that may be caused by simple infiltration; by precisely controlling the rate and location of drug release, the side effects caused by the drug in non-target areas can be reduced. This directional release can reduce the impact on the overall body system, thereby improving the safety and effectiveness of treatment; by fixing the drug molecules to the polymer hydrogel through chemical bonds, the release process can be more persistent and stable. This sustained release can reduce the number of frequent drug administrations required during treatment and improve the convenience and compliance of patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The present invention provides the hydrogen nuclear magnetic resonance spectrum and mass spectrum of diclofenac-PBE.

[0039] Figure 2 The present invention provides the hydrogen nuclear magnetic resonance spectrum and mass spectrum of diclofenac-PBA.

[0040] Figure 3 The present invention provides the hydrogen nuclear magnetic resonance spectrum and mass spectrum of levofloxacin-PBE.

[0041] Figure 4 The present invention provides the hydrogen nuclear magnetic resonance spectrum and mass spectrum of levofloxacin-PBA.

[0042] Figure 5 This is a diagram showing the appearance and transmittance measurement results of the homemade blank hydrogel and responsive drug-releasing hydrogel provided by the present invention.

[0043] Figure 6 This is a graph showing the water content measurement results of the homemade blank hydrogel and responsive drug-releasing hydrogel provided by the present invention and commercially available contact lenses.

[0044] Figure 7 This is a graph showing the mechanical strength measurement results of the homemade blank hydrogel and responsive drug-releasing hydrogel provided by the present invention and commercially available contact lenses.

[0045] Figure 8 This is a graph showing the in vitro release results of the responsive drug-releasing hydrogel provided by the present invention.

[0046] Fig. 9 This is a result diagram of measuring biofilm formation using the crystal violet staining method provided by the present invention.

[0047] Fig.10 This is a graph showing the results of measuring biofilm formation using plate counting provided by the present invention.

[0048] Fig.11 The present invention provides a result diagram of biofilm formation observed using a scanning electron microscope.

[0049] Fig.12 This is a graph showing the clinical scoring results of the bacterial keratitis efficacy experiment provided by the present invention.

[0050] Fig.13 This is a diagram of the tissue sections and corneal thickness measurement results of the bacterial keratitis efficacy experiment provided by the present invention. DETAILED DESCRIPTION

[0051] The invention relates to a functional hydrogel with responsive drug release. The drug-loaded functional hydrogel is a high-molecular-weight functional hydrogel formed by physical crosslinking of polyvinyl alcohol chains induced by freeze-thaw cycles of polyvinyl alcohol and polyvinyl alcohol containing one or more responsive prodrugs.

[0052] The polyvinyl alcohol containing one or more responsive prodrugs is synthesized by two-step reaction. Each polyvinyl alcohol molecule can be loaded with only one drug, and polyvinyl alcohol containing multiple drugs can be obtained after mixing, or one polyvinyl alcohol molecule can be loaded with multiple drugs at the same time. The loaded drugs can be drugs with carboxyl groups or drugs with carboxyl groups after modification.

[0053] Transmittance measurement:

[0054] The contact lens fully hydrated in simulated tear fluid (STF) was wiped clean of surface water and placed on the inner surface of a quartz test tube. The transmittance was measured using a UV-visible spectrophotometer with a wavelength range of 400 to 800 nm.

[0055] Moisture content measurement:

[0056] The polymerized functional hydrogel was placed in a dry state at room temperature for 24 hours to measure the functional hydrogel mass W1, and the dried functional hydrogel was placed in simulated tear fluid for 24 hours to measure the weight of the functional hydrogel as W2. The water content (Water content) of each functional hydrogel was calculated as follows: Water content = (W2-W1) / W1×100%.

[0057] Mechanical strength determination:

[0058] Place the fully hydrated functional hydrogel in the dynamometer fixture and slowly stretch the fixture at a constant speed. Record the breaking tension and length before and after the test, and calculate the tensile strength and elongation at break by the following formula. Tensile strength (δ) = F / (a·b); Elongation at break E% = (L2-L1) / L1×100% Where F is the breaking tension, a is the diameter of the functional hydrogel, b is the thickness of the functional hydrogel, L1 is the length before stretching, and L2 is the breaking length.

[0059] Responsive in vitro release assay:

[0060] In vitro release was performed in a 24-well plate. 1 mL of STF containing 0, 50, or 100 μM H2O2 was added to each well. The drug-loaded functional hydrogel was placed in the release medium, and the 24-well plate was placed in a water bath shaker at a temperature of 35°C and shaken at 50 rpm. At regular intervals, 1 mL of the release medium was taken out, the drug concentration was determined, and 1 mL of fresh release medium was added. In addition, the release medium (100 μM H2O2 or STF) was replaced every 12 hours to study the responsive drug release characteristics of the functional hydrogel.

[0061] The following is a further detailed introduction to a responsive drug-releasing functional hydrogel and a preparation method thereof according to the present invention in conjunction with specific examples. The technical solutions of the present invention include but are not limited to the following examples.

[0062] Example 1: Preparation of functional hydrogel loaded with diclofenac responsive prodrug

[0063] (1) Preparation of intermediate compound diclofenac-PBE

[0064] Diclofenac (1.2 equivalents), 4-hydroxymethylphenylboronic acid pinacol ester (1 equivalent) and 4-dimethylaminopyridine (1.2 equivalents) were completely dissolved in dichloromethane, and then 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.2 equivalents) was added to the mixture. The reactants were stirred at room temperature overnight. The product was purified by column chromatography using n-hexane-ethyl acetate (10:1, v / v) to obtain an oily product, diclofenac-PBE. The results of H NMR and MS are shown in the attached Figure 1 .

[0065] (2) Preparation of intermediate compound diclofenac-PBA

[0066] Diclofenac-PBE (1 equivalent), sodium periodate (3 equivalents) and ammonium acetate (3 equivalents) were dissolved in a mixture of acetone and water (2:1, v / v) in a flask and stirred overnight at room temperature. After removing the acetone by rotary evaporation under reduced pressure, the product was dissolved in ethyl acetate and washed with saturated brine. The upper ethyl acetate layer was separated and purified by column chromatography with dichloromethane-methanol (50:1, v / v) to obtain white powder diclofenac-PBA. The results of H NMR and mass spectrometry are shown in the attached Figure 2 .

[0067] (3) Preparation of polyvinyl alcohol containing diclofenac responsive prodrug

[0068] PVA (400 mg) and DMSO (10 mL) were added to a flask and heated to 90°C under stirring until completely dissolved. After dissolution, the mixture was cooled to room temperature, and diclofenac-PBA (100 mg) and triethylamine (100 mg) were added. The mixture was stirred at room temperature overnight. The product was then dialyzed with deionized water for 24 hours. A diclofenac-polyvinyl alcohol transparent film was obtained by drying at 50°C.

[0069] (4) Preparation of functional hydrogel containing diclofenac responsive prodrug

[0070] 200 mg of polyvinyl alcohol and 40 mg of diclofenac-polyvinyl alcohol were placed in a mixture of 800 μL of DMSO and 200 μL of water. The mixture was stirred at 90°C until dissolved. After cooling to 60°C, it was poured into a mold at 60 mg / tablet, frozen at -20°C for 7 hours, and thawed at room temperature for 3 hours. After repeating this freeze-thaw cycle 4 times, rinse with deionized water to remove DMSO, and a functional hydrogel loaded with diclofenac responsive prodrug was obtained.

[0071] Example 2: Preparation of functional hydrogel loaded with levofloxacin responsive prodrug

[0072] (1) Preparation of the intermediate compound levofloxacin-PBE

[0073] Levofloxacin (1.2 equivalents), 4-hydroxymethylphenylboronic acid pinacol ester (1 equivalent) and 4-dimethylaminopyridine (1.2 equivalents) were prepared. After being completely dissolved in dichloromethane, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.2 equivalents) was added to the mixture. The reactants were stirred at room temperature overnight. The product was separated and purified by preparative liquid chromatography to obtain a light yellow powder product, levofloxacin-PBE. The results of H NMR and mass spectrometry are shown in the attached Figure 3 .

[0074] (2) Preparation of the intermediate compound levofloxacin-PBA

[0075] Levofloxacin-PBE (1 equivalent), sodium periodate (3 equivalents) and ammonium acetate (3 equivalents) were dissolved in a mixture of acetone and water (2:1, v / v) in a flask and stirred overnight at room temperature. After removing the acetone by rotary evaporation under reduced pressure, the product was dissolved in ethyl acetate and washed with saturated brine. The upper ethyl acetate layer was separated and purified by column chromatography to obtain levofloxacin-PBA as a light yellow powder. The results of H NMR and mass spectrometry are shown in the attached Figure 4 .

[0076] (3) Preparation of polyvinyl alcohol containing levofloxacin responsive prodrug

[0077] PVA (400 mg) and DMSO (10 mL) were added to a flask and heated to 90 ° C under stirring until completely dissolved. After dissolution, the mixture was cooled to room temperature, and levofloxacin-PBA (100 mg) and triethylamine (100 mg) were added. The mixture was stirred at room temperature overnight. The product was then dialyzed with deionized water for 24 hours. The levofloxacin-polyvinyl alcohol transparent film was obtained by drying at 50 ° C.

[0078] (4) Preparation of functional hydrogel containing levofloxacin responsive prodrug

[0079] 200 mg of polyvinyl alcohol and 40 mg of levofloxacin-polyvinyl alcohol were placed in a mixture of 800 μL of DMSO and 200 μL of water. The mixture was stirred at 90°C until dissolved. After cooling to 60°C, it was poured into a mold at 60 mg / tablet, frozen at -20°C for 7 hours, and thawed at room temperature for 3 hours. After repeating this freeze-thaw cycle 4 times, rinse with deionized water to remove DMSO, and a functional hydrogel loaded with levofloxacin responsive prodrug was obtained.

[0080] Example 3: Preparation of functional hydrogel loaded with levofloxacin and diclofenac responsive prodrugs

[0081] (1) Diclofenac-PBA and levofloxacin-PBA were prepared in the same manner as in Example 1 and Example 2.

[0082] (2) Preparation of polyvinyl alcohol containing levofloxacin and diclofenac responsive prodrugs

[0083] PVA (340 mg) and DMSO (10 mL) were added to a flask and heated to 90 ° C with stirring until completely dissolved. After dissolution, the mixture was cooled to room temperature, and diclofenac-PBA (40 mg), levofloxacin-PBA (120 mg) and triethylamine (200 mg) were added. The mixture was stirred at room temperature overnight. The product was then dialyzed with deionized water for 24 hours. Levofloxacin & diclofenac-polyvinyl alcohol transparent film was obtained by drying at 50 ° C.

[0084] (3) Preparation of functional hydrogels containing responsive prodrugs of levofloxacin and diclofenac

[0085] 200 mg of polyvinyl alcohol and 40 mg of levofloxacin & diclofenac-polyvinyl alcohol were placed in a mixture of 800 μL DMSO and 200 μL water. The mixture was stirred at 90°C until dissolved. After cooling to 60°C, it was poured into a mold at 60 mg / tablet, frozen at -20°C for 7 hours, and thawed at room temperature for 3 hours. After repeating this freeze-thaw cycle 4 times, rinse with deionized water to remove DMSO, and a functional hydrogel loaded with levofloxacin responsive prodrug was obtained.

[0086] Example 4: Physical Properties Characterization

[0087] The drug-loaded functional hydrogel prepared in Example 3 and a blank polyvinyl alcohol contact lens were used, and the commercially available polyvinyl alcohol contact lens AquaComfort (Alcon Inc.) was used as a control. The results of the physical properties of contact lenses, such as light transmittance, water content and mechanical properties, are shown in the attached Figures 5 to 7 Therefore, the transmittance of the prepared drug-loaded functional hydrogel and blank polyvinyl alcohol contact lens is above 90%, the water content is moderate (65% to 75%), which is close to that of commercially available contact lenses, and the mechanical strength is significantly stronger than that of commercially available contact lenses.

[0088] Example 5: In vitro release

[0089] The functional hydrogel samples prepared in Example 3 were used to study the in vitro drug release of levofloxacin and diclofenac in the hydrogel in simulated tear fluid containing 0, 50 and 100 μM H2O2. The results are shown in the attached figure. Figure 8 As shown, both levofloxacin and diclofenac can adjust their drug release rates according to the concentration of H2O2. Specifically, higher H2O2 concentrations lead to faster drug release, showing a relatively stable zero-order release. In addition, the functional hydrogel can release drugs in the presence of H2O2 and quickly stop drug release in an environment without H2O2, showing an intelligent drug release pattern. This drug release property enables the functional hydrogel to flexibly adjust the drug release rate according to different disease states, maximizing drug utilization while reducing unnecessary side effects.

[0090] Example 6: Antibacterial and anti-biofilm properties

[0091] The drug-loaded functional hydrogel prepared in Example 3 and blank polyvinyl alcohol hydrogel were used to study the antibacterial and anti-biofilm properties of the hydrogel. 2 mL of Staphylococcus aureus bacterial suspension (about 10 6CFU / mL) were added to the wells of a 12-well plate, and blank polyvinyl alcohol hydrogel, blank polyvinyl alcohol hydrogel + 100μM H2O2, responsive drug-release functional hydrogel, and responsive drug-release functional hydrogel + 100μM H2O2 were added and incubated at 37°C for 24 hours to form a biofilm. The biofilm was analyzed using crystal violet staining. The bacteria attached to the functional hydrogel were counted. The hydrogel was placed in sterile water and the bacteria with weaker surface attachment were gently rinsed off. The hydrogel was then placed in a sterile EP tube containing 3mL of sterile water and vortexed vigorously for 2 minutes. The bacteria were counted by serial dilution and plate counting. The results are shown in the attached figure. Fig. 9 and Fig.10 Regardless of whether H2O2 is added or not, the functional hydrogels with responsive drug release have a good ability to prevent biofilm formation, while the blank hydrogels without drugs do not have this property.

[0092] In addition, the hydrogel was gently washed in sterile water and fixed in 1 mL of 2.5% glutaraldehyde for 30 min. After rinsing three times with sterile water, 2 mL of methanol was added for dehydration for 30 min. The methanol was removed and the lens was dried for SEM observation. Fig.11 As shown, the blank hydrogel cannot resist the deposition of bacteria on its surface, while the functional hydrogel with responsive drug release remains smooth without deposition. If bacteria form a biofilm on the surface of the hydrogel, even if the initial infection lesion is treated and removed, the bacteria in the biofilm may re-infect the eye, leading to repeated infection. Therefore, the functional hydrogel prepared by the present invention can reduce the risk of recurrence of infection, maintain the air permeability and hygiene of the hydrogel, and improve the overall wearing comfort when used as an ocular surface insert.

[0093] Example 7: Evaluation of drug efficacy for bacterial keratitis

[0094] A rabbit bacterial keratitis model was established by corneal stroma injection of bacterial solution. 24 hours after inoculation, 18 rabbits were randomly divided into 6 groups: PBS eye drops, levofloxacin eye drops, diclofenac eye drops, levofloxacin + diclofenac eye drops, blank hydrogel and responsive drug release hydrogel. Eye drops were given 50 μL each time, 3 times a day; the hydrogel group was replaced every 5 days for a total of 15 days. Fig.12 As shown in Figure 2, corneal infection in the model group worsened within 15 days, manifested by corneal edema, opacity, and anterior chamber purulent exudate. Corneal perforation occurred, accompanied by significant neovascularization. Due to the adaptive release of the responsive hydrogel, corneal infection was controlled more quickly, which was comparable to the effect of combined application of diclofenac and levofloxacin eye drops. The results of pathological tissue sections and corneal thickness measurements are shown in the attached figure. Fig.13As shown in the figure, the corneal structure of the control group and the blank hydrogel group was abnormal, with obvious infiltration of inflammatory cells and significant corneal thickening. After treatment with the responsive hydrogel, the corneal thickness had returned to normal levels, only about 500 μm, and its effect was comparable to the therapeutic effect of frequent and repeated application of diclofenac and levofloxacin eye drops.

Claims

1. A functional hydrogel with responsive drug release, characterized in that: The responsive drug-releasing functional hydrogel matrix is ​​a high-molecular-weight functional hydrogel formed by physical cross-linking of polyvinyl alcohol chains induced by freeze-thaw cycles of polyvinyl alcohol and polyvinyl alcohol containing one or more responsive prodrugs.

2. The functional hydrogel with responsive drug release according to claim 1, characterized in that: By weight percentage, polyvinyl alcohol accounts for 0% to 90% of the dry weight of the matrix, polyvinyl alcohol containing one or more responsive prodrugs accounts for 10% to 100% of the dry weight of the matrix, and the total is 100%; in the polyvinyl alcohol containing one or more responsive prodrugs, by weight percentage, the drug component accounts for 0.01% to 30% of the weight of the matrix.

3. The functional hydrogel with responsive drug release according to claim 1, characterized in that: The polyvinyl alcohol containing one or more responsive prodrugs has a general chemical structure formula of: R1 is one or more combinations of carboxyl drugs, connected to the benzene ring through an ester group; R2 indicates that the hydrogen atoms on the benzene ring can be replaced by any group; the degree of polymerization of polyvinyl alcohol is 1000-10000; m≥1.

4. The method for preparing the functional hydrogel with responsive drug release according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: placing polyvinyl alcohol and polyvinyl alcohol containing one or more responsive prodrugs in a mixed solvent of DMSO and water; injecting the mixture into a mold after heating and stirring to dissolve, freezing the mixture at -20°C, then thawing the mixture at room temperature, and repeating the freeze-thaw cycle; and washing away the DMSO with deionized water to obtain a functional hydrogel with responsive drug release.

5. The method for preparing the functional hydrogel with responsive drug release according to claim 4, characterized in that: The polyvinyl alcohol containing one or more responsive prodrugs is prepared according to the following steps: (1) subjecting a carboxyl drug, hydroxymethylphenylboronic acid pinacol ester or its derivatives, and a catalyst to an esterification reaction in an organic solvent to obtain an intermediate compound, which is recorded as Drug-PBE; (2) reacting the intermediate compound Drug-PBE with sodium periodate to remove pinacol to obtain an intermediate compound, which is recorded as Drug-PBA; (3) The intermediate compound Drug-PBA undergoes an esterification reaction with the diol structure of polyvinyl alcohol to generate polyvinyl alcohol containing one or more responsive prodrugs.

6. The method for preparing the functional hydrogel with responsive drug release according to claim 5, characterized in that: The preparation method of the intermediate compound Drug-PBE described in step (1) is specifically as follows: dissolving a carboxyl drug, hydroxymethylphenylboronic acid pinacol ester or its derivatives, and 4-dimethylaminopyridine in an organic solvent and stirring at room temperature; adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stirring at room temperature under light-proof conditions until the reaction is completed, and then separating and treating the product to obtain the Drug-PBE; wherein the molar ratio of the carboxyl drug, hydroxymethylphenylboronic acid pinacol ester or its derivatives, 4-dimethylaminopyridine and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is (1-1.2):(1-1.2):(1-1.2):(1.2-1.5); the organic solvent is one of dichloromethane, acetonitrile and acetone; the carboxyl drug is one or more of drugs with carboxyl groups or drugs with carboxyl groups after modification.

7. The method for preparing the functional hydrogel with responsive drug release according to claim 5, characterized in that: The carboxyl-containing drug is a non-steroidal anti-inflammatory drug or an antibacterial drug.

8. The method for preparing the functional hydrogel with responsive drug release according to claim 5, characterized in that: The preparation method of the intermediate compound Drug-PBA described in step (2) is specifically as follows: dissolving Drug-PBE, sodium periodate and ammonium acetate in a solvent, stirring at room temperature until the reaction is completed, and separating and treating the mixture by column chromatography to obtain the product, which is the Drug-PBA; wherein the molar ratio of the Drug-PBE, sodium periodate and ammonium acetate is (1 to 3):(1 to 3):(1 to 3); and the solvent is a mixed solvent of acetone and water.

9. The method for preparing the functional hydrogel with responsive drug release according to claim 5, characterized in that: The preparation method of the polyvinyl alcohol containing one or more responsive prodrugs described in step (3) is as follows: polyvinyl alcohol and DMSO are added to a reaction bottle and heated under stirring until completely dissolved; after dissolution, the mixture is cooled to room temperature, Drug-PBA and an organic base are added, and the reaction is stirred at room temperature. After the reaction is completed, the product is dialyzed in deionized water, and the polyvinyl alcohol containing one or more responsive prodrugs is obtained after drying; wherein the molar ratio of the Drug-PBA, polyvinyl alcohol and the organic base is 1:(1-20):(1-10); the organic base is one of triethylamine, trimethylamine, diisopropylethylamine, DBU and pyridine; the polyvinyl alcohol containing one or more responsive prodrugs is that each polyvinyl alcohol molecule is loaded with only one drug, and polyvinyl alcohol containing multiple drugs is obtained after mixing, or a polyvinyl alcohol molecule is loaded with multiple drugs at the same time.

10. Use of the responsive drug-releasing functional hydrogel according to any one of claims 1 to 3 in the preparation of a drug-device for treating bacterial keratitis.

Citation Information

Patent Citations

  • Preparation method for multiple-response type nanodrug based on combined treatment

    CN112138156A

  • Responsive hydrogel drug delivery system as well as preparation method and application thereof

    CN114796502A

  • High-strength physical crosslinking hydrogel and preparation method thereof

    CN114957722A

  • ROS (reactive oxygen species) response type brain-targeted nanogel double-layer drug release system based on high-molecular polymer as well as preparation method and application thereof

    CN114983930A

  • ROS (reactive oxygen species) response poly-prodrug hydrogel as well as preparation method and application thereof

    CN117717518A

Cited By

  • Prodrug structure with ROS signal response performance and preparation method and application thereof

    CN120504685A

  • A class of prodrug structures with ROS signal response properties, their preparation methods and applications

    CN120504685B